Patents/Assignees

Ambrx, Inc.

15 patents in portfolio

US12612440utility2026
Modified Bovine G-CSF Polypeptides and Their Uses
0 cites
US12577575utility2026
Methods and Compositions for Promoting Non-natural Amino Acid-containing Protein Production
0 cites
US12569566utility2026
Compositions Containing, Methods and Uses of Antibody-tlr Agonist Conjugates
0 cites
US12404512utility2025
Method for Optimizing Antibody Expression
0 cites
US12377294utility2025
Anti-cd3 Antibody Folate Bioconjugates and Their Uses
0 cites
US12286462utility2025
Porcine G-CSF Variants and Their Uses
0 cites
US12059473utility2024
Humanized Anti-prostate -specific Membrane Antigen (PSMA) Antibody Drug Conjugates
0 cites
US12049485utility2024
Interleukin-2 Polypeptide Conjugates and Their Uses
0 cites
US12037405utility2024
Anti-cd70 Antibody Drug Conjugates
0 cites
US11993637utility2024
Modified FGF-21 Polypeptides with Non-naturally Encoded Amino Acids
0 cites
US11851488utility2023
Anti-cd3-folate Conjugates and Their Uses
0 cites
US11851662utility2023
Methods and Compositions for Promoting Non-natural Amino Acid-containing Protein Production
0 cites
US11786578utility2023
Modified Relaxin Polypeptides and Their Uses
0 cites
US11773150utility2023
Antibody Peptide Conjugates That Have Agonist Activity at Both the Glucagon and Glucagon-like Peptide 1 Receptors
0 cites
US11578111utility2023
Porcine G-CSF Variants and Their Uses
0 cites